Novo-Nordisk A/S (NVO) — Analysis Summary
Novo-Nordisk A/S (NVO) has a market cap of $208.18B with year-over-year revenue growth of +11.3%. Net margin stands at 33.1%. The stock trades at a P/E ratio of 13.4.
Key Takeaways
- Revenue changed +11.3% year-over-year
- Net margin of 33.1%
- P/E ratio of 13.4
Compared with its sector, NVO posted revenue growth of +11.3% and trades at a P/E of 13.4.
Novo-Nordisk A/S (NVO)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.80x — current liabilities exceed current assets
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees
69,500
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.43
Dividend Yield
5.17%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.